Skip to main content
Brie Carter Photo
Brie Carter

Brie Carter

GrafaTV Presenter & Finance Editor

TV presenter and finance editor at Grafa, with a Master’s in Commerce from UWA and diverse industry experience in finance, insurance, and media.

Articles by Brie Carter

Grafa
Health

ARS Pharma Wins China Approval for Nasal Epinephrine, Secures Milestone Payment

ARS Pharmaceuticals (NASDAQ:SPRY) said China’s drug regulator has approved neffy 2 mg, an epinephrine nasal spray, for the emergency treatment of Type 1 allergic reactions in adults and children weighing at least 30 kilograms, marking the first epinephrine product authorized for community use in the country.

Read more: ARS Pharma Wins China Approval for Nasal Epinephrine, Secures Milestone Payment
Grafa
Health

Tonix outlines late-stage development path for long-acting Lyme disease antibody

Tonix Pharmaceuticals (NASDAQ:TNXP) said it is advancing development plans for TNX-4800, a long-acting human monoclonal antibody designed for the prevention of seasonal Lyme disease, as the company prepares for regulatory discussions on potential late-stage clinical pathways.

Read more: Tonix outlines late-stage development path for long-acting Lyme disease antibody
Grafa
Technology

Brand Engagement Network secures pharma deal with global agency unit

Brand Engagement Network (NASDAQ:BNAI) said it has entered into a Vendor Services Project Agreement with a unit of a leading global advertising agency to develop a custom artificial-intelligence engagement method for a top-10 global pharmaceutical company’s prescription drug.

Read more: Brand Engagement Network secures pharma deal with global agency unit
Grafa
Industrials

CEA Industries adopts poison pill as Binance-backed YZi Labs seeks board control

CEA Industries (NASDAQ:BNC), which recently rebranded its trading ticker to BNC to reflect its pivot into a digital asset treasury (DAT) model, has implemented a limited-duration stockholder rights plan to thwart a takeover bid.

Read more: CEA Industries adopts poison pill as Binance-backed YZi Labs seeks board control